Lunasin Improves the LDL-C Lowering Efficacy of Simvastatin Via Inhibiting PCSK9 Expression in Hepatocytes and ApoE Mice

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2019 Nov 17

PMID 31731717

Citations 2

Authors

Lili Gu

Yaqin Gong

Cheng Zhao

Yue Wang

Qinghua Tian

Gaoxin Lei

Yalin Liang

WenFeng Zhao

Shuhua Tan

Affiliations

Soon will be listed here.

Abstract

Statins are the most popular therapeutic drugs to lower plasma low density lipoprotein cholesterol (LDL-C) synthesis by competitively inhibiting hydroxyl-3-methyl-glutaryl-CoA (HMG-CoA) reductase and up-regulating the hepatic low density lipoprotein receptor (LDLR). However, the concomitant up-regulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) by statin attenuates its cholesterol lowering efficacy. Lunasin, a soybean derived 43-amino acid polypeptide, has been previously shown to functionally enhance LDL uptake via down-regulating PCSK9 and up-regulating LDLR in hepatocytes and mice. Herein, we investigated the LDL-C lowering efficacy of simvastatin combined with lunasin. In HepG2 cells, after co-treatment with 1 μM simvastatin and 5 μM lunasin for 24 h, the up-regulation of PCSK9 by simvastatin was effectively counteracted by lunasin via down-regulating hepatocyte nuclear factor 1α (HNF-1α), and the functional LDL uptake was additively enhanced. Additionally, after combined therapy with simvastatin and lunasin for four weeks, ApoE mice had significantly lower PCSK9 and higher LDLR levels in hepatic tissues and remarkably reduced plasma concentrations of total cholesterol (TC) and LDL-C, as compared to each monotherapy. Conclusively, lunasin significantly improved the LDL-C lowering efficacy of simvastatin by counteracting simvastatin induced elevation of PCSK9 in hepatocytes and ApoE mice. Simvastatin combined with lunasin could be a novel regimen for hypercholesterolemia treatment.

Citing Articles

Di'ao Xinxuekang Capsule Improves the Anti-Atherosclerotic Effect of Atorvastatin by Downregulating the SREBP2/PCSK9 Signalling Pathway.

Liang J, Li W, Liu H, Li X, Yuan C, Zou W Front Pharmacol. 2022; 13:857092.

PMID: 35571088 PMC: 9096164. DOI: 10.3389/fphar.2022.857092.

Stiffness of aortic arch and carotid arteries increases in -knockout mice with high-fat diet: evidence from echocardiography.

Tang M, Hong L, Li H, Chen W, Tai L, Minshall R Am J Transl Res. 2021; 13(3):1352-1364.

PMID: 33841661 PMC: 8014403.

References

Toth P, Farnier M, Tomassini J, Foody J, Tershakovec A . Statin combination therapy and cardiovascular risk reduction. Future Cardiol. 2016; 12(3):289-315. DOI: 10.2217/fca-2015-0011. View

Rudling M, Angelin B, Stahle L, Reihner E, Sahlin S, Olivecrona H . Regulation of hepatic low-density lipoprotein receptor, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and cholesterol 7alpha-hydroxylase mRNAs in human liver. J Clin Endocrinol Metab. 2002; 87(9):4307-13. DOI: 10.1210/jc.2002-012041. View

Seidah N, Awan Z, Chretien M, Mbikay M . PCSK9: a key modulator of cardiovascular health. Circ Res. 2014; 114(6):1022-36. DOI: 10.1161/CIRCRESAHA.114.301621. View

Wang Y, Martin-McNulty B, Huw L, Da Cunha V, Post J, Hinchman J . Anti-atherosclerotic effect of simvastatin depends on the presence of apolipoprotein E. Atherosclerosis. 2002; 162(1):23-31. DOI: 10.1016/s0021-9150(01)00678-5. View

Dong B, Wu M, Li H, Kraemer F, Adeli K, Seidah N . Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J Lipid Res. 2010; 51(6):1486-95. PMC: 3035512. DOI: 10.1194/jlr.M003566. View

Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah N, Bernier L . Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2004; 24(8):1454-9. DOI: 10.1161/01.ATV.0000134621.14315.43. View

Mandeville W, Arbeeny C . Bile acid sequestrants: their use in combination with other lipid-lowering agents. IDrugs. 2005; 2(3):237-42. View

Pandya V, Rao A, Chaudhary K . Lipid abnormalities in kidney disease and management strategies. World J Nephrol. 2015; 4(1):83-91. PMC: 4317631. DOI: 10.5527/wjn.v4.i1.83. View

Gonzalez de Mejia E, Dia V . Lunasin and lunasin-like peptides inhibit inflammation through suppression of NF-kappaB pathway in the macrophage. Peptides. 2009; 30(12):2388-98. DOI: 10.1016/j.peptides.2009.08.005. View

10.

Grundy S, Stone N . 2018 Cholesterol Clinical Practice Guidelines: Synopsis of the 2018 American Heart Association/American College of Cardiology/Multisociety Cholesterol Guideline. Ann Intern Med. 2019; 170(11):779-783. DOI: 10.7326/M19-0365. View

11.

Postmus I, Trompet S, Deshmukh H, Barnes M, Li X, Warren H . Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun. 2014; 5:5068. PMC: 4220464. DOI: 10.1038/ncomms6068. View

12.

Abifadel M, Varret M, Rabes J, Allard D, Ouguerram K, Devillers M . Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003; 34(2):154-6. DOI: 10.1038/ng1161. View

13.

Scoles D, Xu X, Wang H, Tran H, Taylor-Harding B, Li A . Liver X receptor agonist inhibits proliferation of ovarian carcinoma cells stimulated by oxidized low density lipoprotein. Gynecol Oncol. 2009; 116(1):109-16. DOI: 10.1016/j.ygyno.2009.09.034. View

14.

Kong W, Wei J, Zuo Z, Wang Y, Song D, You X . Combination of simvastatin with berberine improves the lipid-lowering efficacy. Metabolism. 2008; 57(8):1029-37. DOI: 10.1016/j.metabol.2008.01.037. View

15.

Baragetti A, Norata G, Sarcina C, Rastelli F, Grigore L, Garlaschelli K . High density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease. J Intern Med. 2013; 274(3):252-62. DOI: 10.1111/joim.12081. View

16.

Reiner Z . Resistance and intolerance to statins. Nutr Metab Cardiovasc Dis. 2014; 24(10):1057-66. DOI: 10.1016/j.numecd.2014.05.009. View

17.

Sucajtys-Szulc E, Szolkiewicz M, Swierczynski J, Rutkowski B . Up-regulation of liver Pcsk9 gene expression as a possible cause of hypercholesterolemia in experimental chronic renal failure. Mol Cell Biochem. 2015; 411(1-2):281-7. PMC: 4737787. DOI: 10.1007/s11010-015-2590-0. View

18.

Abd El Aal H, Ahmed L, Hassan W, Fawzy H, Moawad H . Combination of carvacrol with simvastatin improves the lipid-lowering efficacy and alleviates simvastatin side effects. J Biochem Mol Toxicol. 2017; 31(12). DOI: 10.1002/jbt.21981. View

19.

Jacobson T, Ito M, Maki K, Orringer C, Bays H, Jones P . National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. J Clin Lipidol. 2014; 8(5):473-88. DOI: 10.1016/j.jacl.2014.07.007. View

20.

Welder G, Zineh I, Pacanowski M, Troutt J, Cao G, Konrad R . High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res. 2010; 51(9):2714-21. PMC: 2918453. DOI: 10.1194/jlr.M008144. View